Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis

被引:1
|
作者
Salvarani, C
Cantini, F
Boiardi, L
Hunder, GG
机构
[1] Arcispedale S Maria Nuova, Serv Reumatol, I-42100 Reggio Emilia, Italy
[2] Osped Prato, Div Med, Rheumatol Unit, Prato, Italy
[3] Mayo Clin, Rochester, MN USA
关键词
giant cell arteritis; Takayasu's arteritis; erythrocyte; sedimentation rate; C-reactive protein; interleukin-6;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A raised erythrocyte sedimentation rate (ESR) is considered a hallmark for the diagnosis of giant cell arteritis (GCA). The American College of Rheumatology 1990 criteria for GCA include ESR greater than or equal to 50 mm/h as one of the five criteria. Although the presence of a normal ESR made GCA less likely, the results of a population-based study showed that the occurrence of a low /normal value in GCA at diagnosis is not rare. Pre-treatment ESR may be a prognostic indicator for duration of treatment. C-reactive protein (CRP) and interleukin-6 (IL-6) may be more sensitive indicators of disease activity than ESR in GCA patients. However, it is unclear whether the use in clinical practice of CRP and IL-6 has some apparent advantage over ESR. ESR is the most often used tool to assess disease activity in Takayasus arteritis (TA). However, some studies have found that ESR and CRP are not able to differentiate patients with clinically active and inactive TA. Furthermore, histopathological studies have shown that over 40% of patients thought to be in clinical remission with normal acute phase reactants have active arteritis. IL-6 could be a promising marker of disease activity in TA; however further studies are required to confirm its usefulness in clinical practice. Other laboratory investigations could be useful in the diagnosis or follow-up of GCA and TA, but more studies are required.
引用
收藏
页码:S23 / S28
页数:6
相关论文
共 50 条
  • [1] Clinical differentiation between giant cell (temporal) arteritis and Takayasu's arteritis
    Michel, BA
    Arend, WP
    Hunder, GG
    JOURNAL OF RHEUMATOLOGY, 1996, 23 (01) : 106 - 111
  • [2] Giant cell and Takayasu arteritis
    Seko, Yoshinori
    CURRENT OPINION IN RHEUMATOLOGY, 2007, 19 (01) : 39 - 43
  • [3] Giant Cell Arteritis and Takayasu Arteritis: Are They Similar or Different?
    Singh, Yogesh Preet
    Bains, Sukhdeep
    Jain, Naman
    INDIAN JOURNAL OF RHEUMATOLOGY, 2025, 20 (01) : 48 - 59
  • [4] Giant cell arteritis versus Takayasu's Arteritis: Two sides of the same coin?
    Mortensen, Peter W.
    Raviskanthan, Subahari
    Chevez-Barrios, Patricia
    Lee, Andrew G.
    SAUDI JOURNAL OF OPHTHALMOLOGY, 2021, 35 (03) : 198 - 203
  • [5] Biological treatments in giant cell arteritis & Takayasu arteritis
    Samson, Maxime
    Espigol-Frigole, Georgina
    Terrades-Garcia, Nekane
    Prieto-Gonzalez, Sergio
    Corbera-Bellalta, Marc
    Alba-Rovira, Roser
    Hernandez-Rodriguez, Jose
    Audia, Sylvain
    Bonnotte, Bernard
    Cid, Maria C.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2018, 50 : 12 - 19
  • [6] Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis—Similarities and Differences
    Ryu Watanabe
    Gerald J. Berry
    David H. Liang
    Jörg J. Goronzy
    Cornelia M. Weyand
    Current Rheumatology Reports, 2020, 22
  • [7] Large vessel vasculitis (giant cell arteritis, Takayasu arteritis)
    Wilke, WS
    BAILLIERES CLINICAL RHEUMATOLOGY, 1997, 11 (02): : 285 - 313
  • [8] Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease?
    Kermani, Tanaz A.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 : 41 - 48
  • [9] The fine line between Takayasu arteritis and giant cell arteritis
    Ari Polachek
    Rachel Pauzner
    David Levartovsky
    Galia Rosen
    Gideon Nesher
    Gabriel Breuer
    Marina Anouk
    Uri Arad
    Hagit Sarvagyl-Maman
    Ilana Kaufman
    Dan Caspi
    Ori Elkayam
    Clinical Rheumatology, 2015, 34 : 721 - 727
  • [10] Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future
    B. Hellmich
    A. F. Águeda
    S. Monti
    R. Luqmani
    Current Rheumatology Reports, 2020, 22